Natco Pharma Limited has issued a regulatory intimation regarding an upcoming meeting of its Board of Directors scheduled for Friday, 25th September, 2026. This meeting is specifically convened to discuss and finalize various matters related to the company's previously approved rights issue.
The rights issue, which was approved by the Board on 9th September, 2026, involves the issuance of equity shares with a face value of ₹2 each, aiming to raise up to ₹1,300 crores. The upcoming board meeting will focus on determining the specific terms of this rights issue, including:
- The rights issue price and related payment mechanism
- The rights entitlement ratio
- The record date for the rights issue
- The timing of the rights issue
The company confirms that this rights issue will be conducted in accordance with the Companies Act, 2013 (as amended), the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018 (as amended), and other applicable laws.
This intimation is issued pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended).
Additionally, the company has announced the closure of the trading window for designated persons, employees, connected persons, and their immediate relatives in accordance with SEBI (Prohibition of Insider Trading) Regulations, 2015. The trading window will remain closed from 23rd September, 2026 until 48 hours after the company intimates the outcome of the board meeting to the stock exchanges.